



03-01-2023

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Symbol: SAKAR

Subject: Announcement under Regulation 30 (LODR) - Sakar Healthcare starting Liquid & Lyophilised Injection unit with tie-up for manufacturing five key molecules in oncology segment

Dear All,

Wish you a very happy and prosperous New Year 2023!

Sakar Healthcare is happy to share an update with the injection unit, a part of its research-driven API-integrated oncology formulation manufacturing unit located at Bavla, Gujarat, India with the advent of this new calendar year 2023.

The integrated sterile injection line from TOFFLON has been aligned at the designated injection block covering over 3500 m². The set-up is comprised of automatic injection filling and labeling tunnels and provisioned with two lyophilisers (freeze-driers) of capacity 10m² and 5m² with nucleation technology to enhance product stability with accuracy. The automatic loading and unloading of vials in lyophiliser under Class A environment with positive pressure isolator make the entire unit robust and regulatory compliant following suitable containment guidelines.

The installation process has just completed, with change part trials have been completed for vials, stoppers and presently various testing procedures are in progress at site to validate and effectively manufacture quality injections- both in liquid and lyophilized forms. The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in anti-cancer segment. The injection unit is all set to commercialize products from April 2023 onwards and have a tie-up to manufacture five key molecules viz. Gemcitabine, Doxorubicin, Epirubicin, Cisplatin and Methotrexate with technology transfer.

This liquid and lyophilized injection manufacturing unit at Sakar shall instill multiple benefits:

- Injection category in oncology are mostly high-priced molecules
- Sterile preparations in injection forms have wider usage pattern
- Makes the vertically integrated oncology plant fully operational
- The five key molecules ranked amongst top 10 in exports and thus will help boost top line
- Boost to leverage existing valued partnership with MNCs and to-Indian Pharma houses- manufacturing and supplying their top brands, ensuring compliance- assuring confidentiality

This is for your information, records and meeting the disclosure requirements under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Thanking you,

Yours faithfully,
for SAKAR HEALTHCARE LIMITED

BHARATKUMAR SUKHLAL SONI
Digitaly signed by BHARATKUMAR SUKHLAL SONI
DN: c=IN, postalCode=382115, o=GUJARAT, s=SAKAR HEALTHCARE LIMITED, email=sukhlal.soni@sakarhealthcare.com, ou=SAKAR HEALTHCARE LIMITED, cn=BHARATKUMAR SUKHLAL SONI

BHARAT SONI
COMPANY SECRETARY &
COMPLIANCE OFFICER